Business Description
Qiagen NV
NAICS : 541720
SIC : 8733
ISIN : NL0015002CX3
Share Class Description:
LTS:0RLT: Ordinary SharesDescription
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.39 | |||||
| Debt-to-EBITDA | 3.78 | |||||
| Interest Coverage | 4.56 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.69 | |||||
| Beneish M-Score | -3.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.2 | |||||
| 3-Year EBITDA Growth Rate | -25.6 | |||||
| 3-Year EPS without NRI Growth Rate | -7.3 | |||||
| 3-Year FCF Growth Rate | 5.2 | |||||
| 3-Year Book Growth Rate | 4.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 7.56 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.64 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.16 | |||||
| 9-Day RSI | 17.67 | |||||
| 14-Day RSI | 16.69 | |||||
| 3-1 Month Momentum % | -3.93 | |||||
| 6-1 Month Momentum % | -3.93 | |||||
| 12-1 Month Momentum % | -3.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.61 | |||||
| Quick Ratio | 3.09 | |||||
| Cash Ratio | 2.12 | |||||
| Days Inventory | 124.42 | |||||
| Days Sales Outstanding | 65.54 | |||||
| Days Payable | 28.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 1.71 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.9 | |||||
| Operating Margin % | 10.11 | |||||
| Net Margin % | 4.23 | |||||
| FCF Margin % | 25.4 | |||||
| ROE % | 2.33 | |||||
| ROA % | 1.42 | |||||
| ROIC % | 3.13 | |||||
| 3-Year ROIIC % | 33.93 | |||||
| ROC (Joel Greenblatt) % | 13.93 | |||||
| ROCE % | 3.35 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 102.67 | |||||
| Forward PE Ratio | 16.66 | |||||
| PE Ratio without NRI | 38.75 | |||||
| Shiller PE Ratio | 34.36 | |||||
| Price-to-Owner-Earnings | 37.14 | |||||
| PEG Ratio | 6.25 | |||||
| PS Ratio | 4.23 | |||||
| PB Ratio | 2.33 | |||||
| Price-to-Tangible-Book | 9.89 | |||||
| Price-to-Free-Cash-Flow | 16.64 | |||||
| Price-to-Operating-Cash-Flow | 12.42 | |||||
| EV-to-EBIT | 51.75 | |||||
| EV-to-Forward-EBIT | 13.8 | |||||
| EV-to-EBITDA | 23.18 | |||||
| EV-to-Forward-EBITDA | 10.73 | |||||
| EV-to-Revenue | 4.32 | |||||
| EV-to-Forward-Revenue | 4.07 | |||||
| EV-to-FCF | 17 | |||||
| Price-to-GF-Value | 0.83 | |||||
| Price-to-Projected-FCF | 1.39 | |||||
| Price-to-Median-PS-Value | 0.8 | |||||
| Price-to-Peter-Lynch-Fair-Value | 7.18 | |||||
| Price-to-Graham-Number | 4.13 | |||||
| Earnings Yield (Greenblatt) % | 1.93 | |||||
| FCF Yield % | 6.05 | |||||
| Forward Rate of Return (Yacktman) % | 9.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qiagen NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,833.13 | ||
| EPS (TTM) (€) | 0.342 | ||
| Beta | 0.23 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 13.98 | ||
| 14-Day RSI | 16.69 | ||
| 14-Day ATR (€) | 0.935582 | ||
| 20-Day SMA (€) | 39.196498 | ||
| 12-1 Month Momentum % | -3.93 | ||
| 52-Week Range (€) | 36.755 - 48.291428 | ||
| Shares Outstanding (Mil) | 216.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qiagen NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qiagen NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Qiagen NV Frequently Asked Questions
What is Qiagen NV(LTS:0RLT)'s stock price today?
The current price of LTS:0RLT is €36.98. The 52 week high of LTS:0RLT is €48.29 and 52 week low is €36.76.
When is next earnings date of Qiagen NV(LTS:0RLT)?
The next earnings date of Qiagen NV(LTS:0RLT) is 2025-04-29 Est..
Does Qiagen NV(LTS:0RLT) pay dividends? If so, how much?
Qiagen NV(LTS:0RLT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers